Finally, we compared the benefit of treatments with βIIV5-3 (a global βIIPKC inhibitor) relative to SAMβA (a selective Mfn1-βIIPKC protein–protein interaction inhibitor) in improving ventricular function and remodeling in heart failure. Here, MFN1 is linked to heart failure.